Celcuity Q3 loss widens on REVTORPYK commercialization costs
CELC•Celcuity reported a Q3 net loss of $73.30 million and no product revenue as REVTORPYK shipments began at quarter-end. Adjusted net loss of $66.80 million and adjusted loss per share of $1.21 beat analyst expectations.
1. Quarterly results
Celcuity reported Q3 operating expenses of $77.30 million as its net loss widened, with no product revenue after REVTORPYK shipments began at quarter-end. Adjusted net loss was $66.80 million, versus an $82.19 million analyst consensus, and adjusted loss per share was $1.21, compared with a $1.43 consensus.
2. Costs and outlook
The company said higher selling, general and administrative expenses were mainly due to hiring and spending to support the REVTORPYK launch. Research and development expenses rose mainly because of higher employee-related and manufacturing costs. Celcuity expects its current cash and investments to finance operations through 2029 and plans to submit VIKTORIA-1 Phase 3 data to global regulators in late 2026 or early 2027.
